Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
Chengdu Tianshizhen Biotechnology is a specialized subsidiary of the Tasly Holding Group, focused on the development and production of high-end functional health products. The company utilizes advanced bioprocessing and extraction technologies to transform traditional natural resources, most notably Pu-erh tea, into standardized health essences under the Deepure brand. Its core business revolves around the research of tea polyphenols and their impact on metabolic health, including lipid-lowering and anti-obesity effects. Based in Chengdu, the company integrates R&D, production, and sales to serve the growing global market for scientifically-backed nutraceuticals. By applying pharmaceutical-grade standards to natural product extraction, the company aims to modernize traditional wellness practices for contemporary consumers.
Beyond the preview
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Follow clinical development from trial design and recruitment through results.
Explore licensing agreements, acquisitions, and the assets behind each deal.
Trace financing activity and the investors behind a company’s development.
Compare peer pipelines by target, modality, and therapeutic area.
Explore technology platforms and the patent landscape around relevant assets.
Connect company news and source material to the questions you’re investigating.
See how Gosset can support your research on Chengdu Tianshizhen Biotechnology.